Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Temozolomide 51Bevacizumab 23Radiotherapy 16Magnetic Resonance Spectroscopy 16Irinotecan 15Carmustine 12Erlotinib Hydrochloride 10Carboplatin 8Surgical Procedures, Operative 6O(6)-benzylguanine 6Imatinib Mesylate 6Filgrastim 6Cyclophosphamide 6Biopsy 6sargramostim 5aldesleukin 5X-Rays 5Thalidomide 5Phantoms, Imaging 5Chemotherapy, Adjuvant 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4Topotecan 4Specimen Handling 4Sirolimus 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Etoposide 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × LY2940680 × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡